Giuseppe Giaccone

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. ncbi Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report
    Jens Voortman
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    BMC Cancer 6:129. 2006
  2. ncbi Clinical impact of novel treatment strategies
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Oncogene 21:6970-81. 2002
  3. ncbi The potential of antiangiogenic therapy in non-small cell lung cancer
    Giuseppe Giaccone
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 13:1961-70. 2007
  4. ncbi Lung cancer
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Cancer Chemother Biol Response Modif 21:445-83. 2003
  5. ncbi HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy
    G Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Ann Oncol 16:538-48. 2005
  6. ncbi Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, 1117 De Boelelaan, Amsterdam, The Netherlands
    J Clin Oncol 23:3235-42. 2005
  7. ncbi Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling
    Maarten L Janmaat
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, PO Box 7057, 1007MB Amsterdam, The Netherlands
    Mol Pharmacol 68:502-10. 2005
  8. ncbi Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 12:6049-55. 2006
  9. ncbi Systemic treatment of malignant thymoma: a decade experience at a single institution
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Am J Clin Oncol 29:336-44. 2006
  10. ncbi Targeting HER1/EGFR in cancer therapy: experience with erlotinib
    Giuseppe Giaccone
    Vrije Universiteit Medical Center, Head of Division of Medical Oncology, 1117 De Boelelaan, Amsterdam, The Netherlands
    Future Oncol 1:449-60. 2005

Detail Information

Publications150 found, 100 shown here

  1. ncbi Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report
    Jens Voortman
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    BMC Cancer 6:129. 2006
    ..Nevertheless, acute development or exacerbation of congestive cardiac failure has been associated with bortezomib treatment...
  2. ncbi Clinical impact of novel treatment strategies
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Oncogene 21:6970-81. 2002
    ..All these novel therapies open a new era of anticancer treatment that will likely complement the currently available therapies in the near future...
  3. ncbi The potential of antiangiogenic therapy in non-small cell lung cancer
    Giuseppe Giaccone
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 13:1961-70. 2007
    ..This review summarizes the most important findings of angiogenesis inhibitors in NSCLC and discusses the potential for the use of these novel agents in different settings of NSCLC...
  4. ncbi Lung cancer
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Cancer Chemother Biol Response Modif 21:445-83. 2003
  5. ncbi HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy
    G Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Ann Oncol 16:538-48. 2005
    ..This may help us to preselect responsive patients, tailor the dose according to the individual's tolerability, or monitor these agents to optimise/interrupt therapy at an early stage...
  6. ncbi Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, 1117 De Boelelaan, Amsterdam, The Netherlands
    J Clin Oncol 23:3235-42. 2005
    ....
  7. ncbi Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling
    Maarten L Janmaat
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, PO Box 7057, 1007MB Amsterdam, The Netherlands
    Mol Pharmacol 68:502-10. 2005
    ..In summary, our results identify ErbB3 and the downstream PI3K-Akt pathway as important determinants of the cytotoxic activity of KF in vitro...
  8. ncbi Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 12:6049-55. 2006
    ..Erlotinib has proven activity in pretreated patients with advanced non-small cell lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC and assessed biological predictors of outcome...
  9. ncbi Systemic treatment of malignant thymoma: a decade experience at a single institution
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Am J Clin Oncol 29:336-44. 2006
    ..Thymic malignancies are rare tumors on the superior anterior mediastinum. Treatment of advanced stages includes chemotherapy. The objective of this analysis was to review the treatment of this disease in the past decade...
  10. ncbi Targeting HER1/EGFR in cancer therapy: experience with erlotinib
    Giuseppe Giaccone
    Vrije Universiteit Medical Center, Head of Division of Medical Oncology, 1117 De Boelelaan, Amsterdam, The Netherlands
    Future Oncol 1:449-60. 2005
    ..Erlotinib has demonstrated the clinical activity in a variety of solid tumors, and has recently demonstrated improvements in survival in large Phase III trials, in non-small-cell lung cancer and pancreatic cancer...
  11. ncbi Lung cancer
    Giuseppe Giaccone
    Division of Medical Oncology, Vrijie Universiteit Medical Center, Amsterdam and Martini Hospital, Groningnen, Amsterdam, The Netheslands
    Cancer Chemother Biol Response Modif 22:413-42. 2005
  12. ncbi Targeted therapy in non-small cell lung cancer
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, Amsterdam 1081, The Netherlands
    Lung Cancer 38:S29-32. 2002
    ..This "targeted therapy" represents a new generation of anticancer treatment and a chance to revitalize the moribund state of NSCLC treatment...
  13. ncbi A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, HV 1081 Amsterdam, The Netherlands
    Clin Cancer Res 8:3702-9. 2002
    ..We performed a dose escalation study of KRN7000 in advanced cancer patients...
  14. ncbi Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, 1117 De Boelelaan, Amsterdam, The Netherlands
    J Clin Oncol 23:6854-64. 2005
    ..We assessed whether Bec2/bacille Calmette-Guerin (BCG) vaccination prolongs survival in patients with limited-disease small-cell lung cancer (SCLC) after a major response to chemotherapy and chest radiation...
  15. ncbi EGFR inhibitors: what have we learned from the treatment of lung cancer?
    Giuseppe Giaccone
    Department of Medical Oncology, Free University Medical Center, 1117 De Boelelaan, HV 1081 Amsterdam, Netherlands
    Nat Clin Pract Oncol 2:554-61. 2005
    ..Prospective validation of biological and clinical markers of sensitivity needs to be performed...
  16. ncbi Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1
    Giuseppe Giaccone
    Vrije Universiteit Medical Center, Department of Oncology, De Boelelaan 1117, 1081 Amsterdam, The Netherlands
    J Clin Oncol 22:777-84. 2004
    ..Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a phase I trial of gefitinib in combination with gemcitabine and cisplatin showed favorable tolerability...
  17. ncbi Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group
    G Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, 1117 De Boelelaan, HV 1081 Amsterdam, The Netherlands
    Eur J Cancer 40:667-72. 2004
    ..Median survival of all patients treated was 5.8 months (95% CI 4.2-7.9). In conclusion, glufosfamide administered by a 1-h infusion every 3 weeks has modest activity in advanced NSCLC patients after one prior platinum-based chemotherapy...
  18. ncbi Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors
    G Giaccone
    Department of Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Ann Oncol 15:831-8. 2004
    ....
  19. ncbi Update on the systemic treatment of lung cancer
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, 1117 De Boelelaan, HV 1081 Amsterdam, The Netherlands
    Cancer Chemother Biol Response Modif 20:697-716. 2002
  20. ncbi Phase II trial of ZD0473 as second-line therapy in mesothelioma
    G Giaccone
    Free University Hospital, Amsterdam, The Netherlands
    Eur J Cancer 38:S19-24. 2002
    ..This trial also demonstrates that clinical trials in second-line mesothelioma patients are feasible...
  21. ncbi Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells
    Linda E Bröker
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Res 64:27-30. 2004
    ..Interestingly, inhibition of cathepsin B prevents the appearance of multinucleated cells, an early characteristic of MSA-induced cell death, pointing to a central, proximal role for cathepsin B in this novel cell death pathway...
  22. ncbi Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460
    Jens Voortman
    Department of Medical Oncology, CCA 2 36, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Mol Cancer Ther 6:1046-53. 2007
    ..Our preclinical results support further investigation of bortezomib-based therapies as a possible new treatment modality for NSCLC...
  23. ncbi Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways
    Maarten L Janmaat
    VU University Medical Center, MB 1007 Amsterdam, The Netherlands
    Clin Cancer Res 9:2316-26. 2003
    ..Together, these data suggest that persistent activity of either of these signaling pathways is involved in the lack of sensitivity of NSCLC cell lines to EGFR inhibitors...
  24. ncbi Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target
    Marielle I Gallegos Ruiz
    Department of Medical Oncology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
    PLoS ONE 3:e0001722. 2008
    ..Understanding the molecular events in non-small cell lung cancer (NSCLC) is essential to improve early diagnosis and treatment for this disease...
  25. ncbi Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export
    Miriam Ferrer
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Hum Mol Genet 14:1271-81. 2005
    ..Taken together, these findings indicate that FANCA can be actively exported out of the nucleus by CRM1, revealing a new mechanism to regulate the function of the FA protein complex...
  26. ncbi Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells
    Hans J J van der Vliet
    Department of Medical Oncology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
    Cancer Res 63:4101-6. 2003
    ....
  27. ncbi The immunoregulatory role of CD1d-restricted natural killer T cells in disease
    Hans J J van der Vliet
    The Departments of Pathology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
    Clin Immunol 112:8-23. 2004
    ..Here, we review the immunoregulatory role of NKT cells in disease and discuss NKT cell based immunotherapeutic strategies...
  28. ncbi A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors
    Jens Voortman
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 13:3642-51. 2007
    ..To establish maximum tolerated dose (MTD) and tolerability of two schedules of bortezomib in combination with cisplatin and gemcitabine as first-line treatment of patients with advanced solid tumors...
  29. ncbi Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells
    Linda E Bröker
    Department of Medical Oncology, Vrije University Medical Center, 1081 HV Amsterdam, The Netherlands
    Cancer Res 62:4081-8. 2002
    ....
  30. ncbi Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas
    Giuseppe Giaccone
    Department of Medical Oncology, VU Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 4:1270-3. 2009
    ..Imatinib has no major activity in this rare tumor. Given the small number of patients treated in this study, selection based on presence of c-KIT mutations might be warranted...
  31. ncbi Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation
    Agnieszka Checinska
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, CCA 2 44 1081 HV Amsterdam, The Netherlands
    Exp Cell Res 313:1215-24. 2007
    ..Our findings indicate that the use of small molecule Smac mimic, when combined with an apoptotic trigger, may have therapeutic potential for the treatment of NSCLC...
  32. ncbi Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients
    Barbara Vischioni
    Division of Medical Oncology, Academic Hospital Vrije Universiteit, 1117 De Boelelaan, HV 1081 Amsterdam, The Netherlands
    Mol Cancer Ther 5:2905-13. 2006
    ..007) in the overall series of NSCLC samples. Taken together, our results suggest that aurora B may represent a valid target in NSCLC...
  33. ncbi The role of new agents in the treatment of non-small cell lung cancer
    Linda E Bröker
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Eur J Cancer 38:2347-61. 2002
    ..Promising results have thus far been obtained with some of these therapies. This review describes the role of new therapeutic agents in the treatment of NSCLC...
  34. ncbi DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens
    Leticia G Leon
    Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam CCA 1 52, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Curr Drug Metab 12:956-65. 2011
    ....
  35. ncbi Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres
    Susanne M A Lens
    Department of Medical Oncology, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands
    Mol Biol Cell 17:1897-909. 2006
    ..Importantly, our data show that the function of the CPC at the centromere can be separated from its function at the central spindle and that execution of cytokinesis does not require prior concentration of the CPC at centromeres...
  36. ncbi Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
    Giuseppe Giaccone
    Free University Medical Center, Amsterdam, The Netherlands
    J Cancer Res Clin Oncol 135:467-76. 2009
    ..Epidermal growth factor receptor (EGFR) staining was assessed retrospectively in relation to survival response to gefitinib in combination with chemotherapy...
  37. ncbi Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells
    Cecilia Ceresa
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Mol Cancer Ther 8:1026-36. 2009
    ..The increase of deoxycytidine kinase and dFdCTP might contribute to this synergistic interaction and supports its further clinical investigation...
  38. ncbi Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460
    Cynthia Huisman
    Department of Medical Oncology, University Hospital Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Clin Cancer Res 8:596-606. 2002
    ..This finding is in sharp contrast with the largely caspase-dependent response elicited by DNA-damaging agents in these cells. We speculate on therapeutic implications...
  39. ncbi Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib
    Elisa Giovannetti
    Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam CCA 1 52, Amsterdam, The Netherlands
    Mol Cancer Ther 9:581-93. 2010
    ....
  40. ncbi Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours
    Hester van Cruijsen
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Eur J Cancer 46:901-11. 2010
    ..Combination treatment with cediranib and gefitinib, an EGFR signalling inhibitor, was evaluated in patients with advanced solid tumours...
  41. ncbi Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain
    Matheus M de Gunst
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Mol Cancer 6:56. 2007
    ..The phenotypical consequences of different EGFR mutations may vary dramatically, but the majority of uncommon EGFR mutations have never been functionally evaluated...
  42. ncbi Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA
    Miriam Ferrer
    Department of Medical Oncology, Division of Gene Therapy, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Gene Ther 11:539-46. 2004
    ....
  43. ncbi Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975
    Egbert F Smit
    Department of Pulmonogy, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 21:3909-17. 2003
    ..Materials and..
  44. ncbi Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2
    Barbara Vischioni
    Department of Medical Oncology, VU University Medical Center, HV1081 Amsterdam, The Netherlands
    Exp Cell Res 298:535-48. 2004
    ..Our results identify molecular mechanisms that contribute to regulate the subcellular localization of cIAP1 and cIAP2. Translocation between different cell compartments may add a further level of control for cIAP1 and cIAP2 activity...
  45. ncbi FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy
    Miriam Ferrer
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Lung Cancer 6:250-4. 2005
    ..In conclusion, the activation status of the FA pathway had no value in predicting sensitivity to platinum-based chemotherapy in patients with advanced NSCLC...
  46. ncbi Cell death independent of caspases: a review
    Linda E Bröker
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 11:3155-62. 2005
    ..Here we review the various models of PCD and their death pathways at molecular and organelle level and discuss the relevance of the growing knowledge of caspase-independent cell death pathways for cancer...
  47. ncbi A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183
    Linda E Bröker
    VU University Medical Center, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Clin Cancer Res 13:3906-12. 2007
    ..Additionally, the pharmacokinetics and possible antitumor activity were studied...
  48. ncbi Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
    Clara Lemos
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands
    Pharmacogenomics 12:159-70. 2011
    ..The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients...
  49. ncbi Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity
    Linda E Bröker
    VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 12:1760-7. 2006
    ..BMS-275183 is an orally administered C-4 methyl carbonate analogue of paclitaxel. We did a dose-escalating phase I study to investigate its safety, tolerability, pharmacokinetics, and possible antitumor activity...
  50. ncbi The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients
    Martijn R Meijerink
    Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands
    Eur Radiol 17:1700-13. 2007
    ..In conclusion, CTP is feasible in showing changes of perfusion induced by anti-angiogenic therapy...
  51. ncbi The expression of TUCAN, an inhibitor of apoptosis protein, in patients with advanced non-small cell lung cancer treated with chemotherapy
    Agnieszka Checinska
    Departments of Medical Oncology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Anticancer Res 26:3819-24. 2006
    ..027). CONCLUSION: Our results suggest that differential localization of TUCAN may be a prognostic factor for NSCLC, despite the lack of predictive value for response to chemotherapy...
  52. ncbi Genetic heterogeneity in patients with multiple neoplastic lung lesions: a report of three cases
    Marielle I Gallegos Ruiz
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 2:12-21. 2007
    ..A better understanding of the molecular alterations present in the different lesions may help in defining this relation...
  53. ncbi TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib
    Jens Voortman
    Department of Medical Oncology, CCA 2 36, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Mol Cancer Ther 6:2103-12. 2007
    ..Our preclinical data indicate that combination therapy of TRAIL and bortezomib may be an effective strategy for NSCLC...
  54. ncbi Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival
    Hester van Cruijsen
    Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 14:5884-92. 2008
    ..We investigated the effect of sunitinib, a tyrosine kinase inhibitor of fms-like tyrosine kinase-3, KIT, and vascular endothelial growth factor receptors, on myeloid differentiation in renal cell cancer (RCC) patients...
  55. ncbi Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner
    Miriam Ferrer
    Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands
    Exp Cell Res 286:381-95. 2003
    ....
  56. ncbi TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells
    Agnieszka Checinska
    Department of Medical Oncology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    BMC Cancer 6:166. 2006
    ..The aim of the present study was to investigate the mechanism of caspase-9 inhibition, with a focus on a possible role of TUCAN as caspase-9 inhibitor and a determinant of chemosensitivity in NSCLC cells...
  57. ncbi Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients
    Maarten L Janmaat
    Department of Medical Oncology, Vreije Universiteit Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 24:1612-9. 2006
    ..The selection of esophageal cancer patients for future studies with EGFR-TKIs based on the level of EGFR expression in their tumors or SCC histology should be considered...
  58. ncbi Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30
    Lars R Perk
    Department of Otolaryngology Head and Neck Surgery, VU University Medical Centre, De Boelelaan 1117, P O Box 7057, Amsterdam 1007 MB, The Netherlands
    Eur J Nucl Med Mol Imaging 35:1857-67. 2008
    ..We considered the potential of PET with either (89)Zr-labelled (residualising radionuclide) or (124)I-labelled (non-residualising radionuclide) DN30 for imaging of Met-expressing tumours...
  59. ncbi Global histone modifications predict prognosis of resected non small-cell lung cancer
    Fabrice Barlesi
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 25:4358-64. 2007
    ..Epigenetic modifications may contribute to the development and progression of cancer. We investigated whether epigenetic changes involving multiple histones influence prognosis of non-small-cell lung cancer (NSCLC) patients...
  60. ncbi Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC)
    Elisa Giovannetti
    Dept of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Curr Drug Targets 11:12-28. 2010
    ....
  61. ncbi The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells
    Jens Voortman
    Department of Medical Oncology, VU University Medical Center, 1081HV Amsterdam, The Netherlands
    Mol Cancer 6:73. 2007
    ..Further studies in NSCLC are warranted to elucidate underlying mechanisms...
  62. ncbi Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer
    J R Kroep
    Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 58:509-16. 2006
    ..CONCLUSIONS: Gemcitabine and cisplatin pharmacology were not influenced by the combination with one of the other agents, while paclitaxel has a lower clearance in combination with cisplatin as compared to gemcitabine...
  63. ncbi EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens
    Marielle I Gallegos Ruiz
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol 29:257-64. 2007
    ..Furthermore, we compare the sensitivity of the analysis using genomic DNA (gDNA) versus RNA...
  64. ncbi Novel approaches to the treatment of non-small cell lung cancer
    Carlos G Ferreira
    Department of Medical Oncology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands
    Crit Rev Oncol Hematol 41:57-77. 2002
    ..Finally, perspectives of future applications and impact on the treatment of NSCLC are also discussed...
  65. ncbi Subcellular localization of CrmA: identification of a novel leucine-rich nuclear export signal conserved in anti-apoptotic serpins
    Jose A Rodriguez
    Department of Medical Oncology, VU University Medical Center, HV1081 Amsterdam, The Netherlands
    Biochem J 373:251-9. 2003
    ....
  66. ncbi Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Semin Oncol 29:47-9. 2002
    ..Further follow-up and analysis of quality of life may clarify this possible difference in treatment outcome...
  67. ncbi Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183
    Linda E Bröker
    VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 14:4186-91. 2008
    ..Pharmacokinetic sampling was done up to 72 hours after the first four doses and analyzed with a validated liquid chromatography/mass spectrometry assay...
  68. ncbi Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy
    C Huisman
    Department of Pulmonary Diseases, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    Br J Cancer 85:1456-61. 2001
    ..Since the activity of this regimen is encouraging, it is probably best studied in untreated patients...
  69. ncbi Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)
    N Van Zandwijk
    Netherlands Cancer Institute and Free University, Amsterdam, The Netherlands
    J Clin Oncol 18:2658-64. 2000
    ....
  70. ncbi EGFR inhibitors in lung cancer
    Jan Buter
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Oncology (Williston Park) 19:1707-11; discussion 1711-2, 1720-3. 2005
    ..Newer drugs inhibiting more than one receptor pathway are being investigated in order to find activity in a broader group of patients...
  71. ncbi Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer
    A C Dingemans
    Department of Medical Oncology, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands
    Lung Cancer 32:117-28. 2001
    ..In one tumor sample, a newly described mutation in the B/DNBS region of the topo IIalpha gene was detected, which does not appear to be related to drug resistance...
  72. ncbi Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
    C J van Groeningen
    University Hospital Vrije Universiteit, Netherlands Cancer Institute, and NDDO Oncology, Amsterdam, The Netherlands
    J Clin Oncol 18:2772-9. 2000
    ....
  73. ncbi Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer
    J R Kroep
    Department of Medical Oncology, VU Medical Centre, Amsterdam, The Netherlands
    Ann Oncol 15:230-5. 2004
    ..For oesophageal cancer there is no effective standard therapy. We studied the feasibility and efficacy of the cisplatin-gemcitabine combination chemotherapy in patients with unresectable oesophageal cancer...
  74. ncbi Medical treatment of non-small-cell lung cancer
    J Buter
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Ann Oncol 16:ii229-32. 2005
  75. ncbi Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling
    C Huisman
    Department of Pulmonary Diseases, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    Lung Cancer 33:267-75. 2001
    ..Frequent omission of gemcitabine day 15 is a limitation of this schedule. This should be an important factor in a practical approach to decide on the most optimal schedule of the cisplatin plus gemcitabine combination...
  76. ncbi CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin
    Jose A Rodriguez
    Department of Medical Oncology, VU University Medical Center, Amsterdam, HV1081, The Netherlands
    Exp Cell Res 275:44-53. 2002
    ..These data suggest that active transport between the nucleus and cytoplasm may constitute an important regulatory mechanism for Survivin function...
  77. ncbi How should we analyse FDG PET studies for monitoring tumour response?
    Adriaan A Lammertsma
    Department of Nuclear Medicine and PET Research, VU University Medical Centre, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 33:16-21. 2006
    ..For a new drug, first a pilot study is performed to assess whether it affects this relationship. Based on this pilot, it is decided whether or not a simplified clinical method can be used in further studies...
  78. ncbi Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS
    Connie R Jimenez
    OncoProteomics Laboratory, Department of Medical Oncology, VU Medical Center, Amsterdam, The Netherlands Department of Molecular and Cellular Neurobiology, Center for Medical Systems Biology Neurogenomics and Cognitive Research, Vrije Universteit, Amsterdam, The Netherlands
    Proteomics Clin Appl 1:598-604. 2007
    ..In conjunction with the KingFisher® 96, the whole serum peptide capture procedure is high-throughput (˜20 min per isolation of 96 samples in parallel), thereby facilitating large-scale disease profiling studies...
  79. ncbi Natural Killer T cells
    Hans J J van der Vliet
    Lancet Oncol 3:574. 2002
  80. ncbi The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors
    Godefridus J Peters
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 10:4072-6. 2004
    ..4:1...
  81. ncbi The role of gefitinib in lung cancer treatment
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 10:4233s-4237s. 2004
    ..Additional studies are indicated to assess the possible role of gefitinib in the maintenance of patients who received chemotherapy or chemoradiotherapy. Studies investigating gefitinib as first-line monotherapy are also required...
  82. ncbi Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors
    Maarten L Janmaat
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Oncologist 8:576-86. 2003
    ..Of these, small-molecule tyrosine kinase inhibitors represent one of the most promising classes of anticancer agents. Here, we describe the status of small-molecule EGFR tyrosine kinase inhibitors in preclinical and clinical development...
  83. ncbi Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer
    Hester van Cruijsen
    Department of Medical Oncology, VU University Medical Center, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    BMC Cancer 9:180. 2009
    ....
  84. ncbi Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)
    Jose Belderbos
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Eur J Cancer 43:114-21. 2007
    ..A randomised phase III study was performed comparing sequential (S) and concurrent (C) chemo-radiotherapy (CRT) in non-small cell lung cancer (NSCLC) patients...
  85. ncbi 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients
    H H Backus
    Department of Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    Ann Oncol 12:209-16. 2001
    ..Since Fas mediated cell killing is important for cytotoxic T cells this indicates that clinical studies combining immunotherapy for activation of T cells and chemotherapy using 5-FU might be very effective...
  86. ncbi Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown
    J A Rodriguez
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Oncogene 25:4867-79. 2006
    ..Furthermore, the specific effect of INCENP and Survivin on the localization of Aurora B and Borealin, respectively, suggests that different complexes of CPPs may exist not only during mitosis, as recently reported, but also before NEB...
  87. ncbi DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?
    E Smitskamp-Wilms
    Department of Oncology, Free University Hospital, Amsterdam, The Netherlands
    Br J Cancer 72:917-21. 1995
    ..The degree of variation found for DTD (range 4-250 nmol min-1 mg-1), was not observed for these enzymes (CP450R, 0.8-7.8 nmol cytochrome c min-1 mg-1; Cb5R, 3.5-27.6 nmol min-1 mg-1).(ABSTRACT TRUNCATED AT 250 WORDS)..
  88. ncbi Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
    J R Kroep
    Department of Medical Oncology, University Hospital Vrije Universiteit, P O Box 7057, Amsterdam, MB, 1007, The Netherlands
    Br J Cancer 83:1069-76. 2000
    ..However, since paclitaxel increased dFdCTP accumulation, gemcitabine incorporation into RNA and the apoptotic index, the administration of paclitaxel prior to gemcitabine might be favourable as compared to reversed sequences...
  89. ncbi Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor
    H van Cruijsen
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Clin Dev Immunol 2007:17315. 2007
    ..In conclusion, TK inhibition of VEGFR with AZD2171 does not restore the defective PBDC differentiation observed in advanced cancer patients...
  90. ncbi Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer
    S M De Lange
    Department of Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    Eur J Cancer 38:1212-7. 2002
    ..Although the toxicity of this treatment was occasionally severe, the response and survival are encouraging and warrant further studies of this combination...
  91. ncbi FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer
    N Croles
    Department of Medical Oncology, Free University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Neth J Med 62:242-5. 2004
    ..The median progression-free survival was 5.8 months and the median overall survival was 8.5 months. CONCLUSION: For heavily pretreated patients with MCC, the FOLFOX3 regimen is a fairly safe and effective treatment...
  92. ncbi The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992)
    P Baas
    The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Eur J Cancer 39:353-7. 2003
    ..We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted...
  93. ncbi Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11
    D Oosterhoff
    Department of Medical Oncology, Division of Gene Therapy, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Br J Cancer 92:882-7. 2005
    ..Therefore, Ad.C28-sCE2 holds promise in gene therapy approaches for the treatment of colon carcinoma...
  94. ncbi Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule
    E Boven
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Br J Cancer 92:1636-43. 2005
    ..The recommended dose of 18.4 g m(-2) enabled safe reduction of the saline hydration schedule for cisplatin to 1000 ml. Further studies will assess whether BNP7787 offers protection against platinum-related late side effects...
  95. ncbi Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors
    G J Peters
    Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 52:1-12. 2003
    ....
  96. ncbi Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer
    B Vischioni
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Ann Oncol 15:1654-60. 2004
    ..Expression and localization of survivin did not correlate with response to chemotherapy. CONCLUSIONS: Our results indicate that differential localization of survivin may be a prognostic factor for NSCLC. Further studies are warranted...
  97. ncbi Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL
    M A I Abou El Hassan
    Department of Medical Oncology, VU University Medical Centre, 1007 MB Amsterdam, The Netherlands
    Br J Cancer 91:171-7. 2004
    ..These findings further indicate that the combined use of chemo/radiotherapy and adenovirus-produced full-length TRAIL may provide a valuable treatment option for NSCLC...
  98. ncbi Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues
    A M Dingemans
    Department of Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    Ann Oncol 7:625-30. 1996
    ..The recently discovered LRP protein has been shown to be involved in drug resistance and possibly in detoxification processes...
  99. ncbi Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
    G Giaccone
    Division of Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    J Clin Oncol 16:2133-41. 1998
    ..To compare two cisplatin based chemotherapy schedules in patients with advanced non-small-cell lung cancer (NSCLC)...
  100. ncbi Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients
    C G Ferreira
    Department of Medical Oncology, Academic Hospital Vrije Universitiet, Amsterdam, The Netherlands
    Ann Oncol 12:799-805. 2001
    ..3) The relation between expression of IAPs and chemosensitivity in cancer patients may be more complex than anticipated by in vitro data...
  101. ncbi Pleura mesothelioma: combined modality treatments
    T Cerny
    Vrije Universiteit Medical Center, Division of Medical Oncology, Amsterdam, The Netherlands
    Ann Oncol 13:217-25. 2002